Why Capricor (CAPR) Rose 58%: The FDA Decision Went Away, and I Called It Wrong

TL;DR

• CAPR closed at $6.65 on August 14, up 57.96% from Thursday's $4.21, on about 65 million shares against a three-month average near 3.1 million. More stock changed hands in one session than the company has outstanding.
• The FDA did not decide anything. Capricor said on Thursday's 4:30pm call that it will amend the deramiocel BLA to a narrower indication, and that the agency will push the August 22 action date out once the amendment arrives.
• The narrower label is the endpoint that worked. Upper limb function hit at p=.029; the cardiac measure behind the cardiomyopathy claim missed at p=.09. Capricor is refiling on the winning half.
• Our August 12 preview got the data right and the trade wrong. The logged pass on any options structure into August 22 is graded a loss against a 69% move off the spot it was struck at.
• The move faded all day. Reuters had CAPR at $9.18, up 118%, before the bell. It opened at $7.68 and closed near the bottom of a $6.05-$8.15 range.

Why Did Capricor Stock Go Up 58%?

Capricor told investors it will stop asking the FDA the question it was going to lose. On Thursday's 4:30pm earnings call, CEO Linda Marbán said the company will submit an amendment to the deramiocel Biologics License Application carrying 24-month open-label extension data from HOPE-3, aimed at "a refined indication focused on the primary endpoint," and that the FDA "has indicated it is willing to review this amendment and upon receipt to extend the PDUFA action date accordingly" (BioSpace). Reuters and Parent Project Muscular Dystrophy carry the same account, PPMD spelling out that the August 22 date "will be extended" on receipt.

Then Cantor Fitzgerald upgraded the stock to Overweight from Neutral before the open, with a 12-month target of $28, up from the $3.50 it had set two weeks earlier (Investing.com). Cantor's note points at the amendment. No new efficacy data arrived this week.

The Board

Peak +118% before the bell, +57.96% at the close, and no FDA answer either way.

Nobody Approved Anything

The thing being celebrated is a delay. Eight days before a decision the market had priced at close to zero chance of going well, the company withdrew the losing half of its application and the agency agreed to restart the clock. That is a real improvement in the odds of eventually getting a drug approved, and it is also the company conceding the point the advisory committee made on July 29 when it voted 9 to 3 that the evidence did not support effectiveness in Duchenne cardiomyopathy.

The new path is less settled than a 58% session implies. Nobody has said how long the extension runs: a major amendment normally buys the FDA three months, and PPMD notes that a non-major one carries no defined clock at all. And as of Friday's close the amendment had not been submitted. The extension is a stated intention on both sides, not a docketed date.

+118% at 6am, +58% at 4pm

The tape spent the whole session giving the news back. Reuters had $9.18 before the bell. The stock opened at $7.68, ran to $8.15, and closed at $6.65, which is 27.6% below the premarket peak and near the low of the day. Two quote feeds agree on the close within a cent: stockanalysis.com has $6.65, +57.96%, and investing.com has $6.66, +58.19%, both against $4.21.

The close is the number worth keeping. It puts the market cap near $386 million against $237.9 million of cash at June 30, so the drug programme is being valued around $149 million, up from roughly $7 million at Thursday's bell. Volume was about 21 times the three-month average, which is what a repricing looks like when almost nobody owned the thing going in.

Grading My Own Call

Two days before this, on August 12, I wrote that the setup into August 22 "looks more like a second rejection than a Replimune-style reversal," and closed with the line that it "is not a stock I'd be adding into the decision on hope that the FDA sides with the minority of its own panel." The logged play was a pass on any directional options structure, struck against a spot of $3.90-$3.95.

CAPR closed at $6.65. Against the $3.93 spot in that log the move is +69.2%; against the $4.19 close on the day the piece published it is +58.7%. On this site's scoring rules a pass is graded as the trade the reader did not make, so that is a loss, and it goes into the Track Record ledger as one. The July scorecard found the costliest calls in that audit were passes too, which is the pattern repeating rather than a new one.

What the piece did get right was the diagnosis. It spent its longest section on the split in HOPE-3, arguing that the drug's problem was specifically that the failed endpoint, LVEF, "is the one that was supposed to justify a cardiomyopathy label in the first place." Capricor's response two days later was to drop the cardiomyopathy label and refile on upper limb. The analysis pointed straight at the move the company made. I just did not think the company would make it before the decision.

A PDUFA Date Is Not an Expiry

Here is the mistake, and it generalises. I treated August 22 as a settlement date with two possible outcomes: approval or rejection. An options expiry works that way. A regulatory date does not, because the applicant is a participant rather than a spectator, and a company staring at a decision it expects to lose can amend, withdraw, or refile, all of which stop the clock.

So the outcome set was never two items. It was three, and the third one, "the question changes and the date moves," was the one I left out. It is also the outcome with the largest price effect in a name where the market had marked the drug to about $6 million, because removing a near-certain no is worth more than improving the odds on a coin flip.

Worth naming the asymmetry I did see and did not act on: a company with $237.9 million of cash and a $244 million market cap is one where the equity is priced as a cash shell. Anything that puts a drug back into the valuation moves it violently. My August 12 piece said as much, then logged a pass anyway.

The Lancet Paper Everyone Filed as Friday News

Several outlets ran Friday's move as "Lancet data and analyst upgrades collide." The Lancet published HOPE-3 on July 29, 2026, per Capricor's own release, the same day the advisory committee voted the drug down. It was three weeks old on Friday and it is the same 54% slowing of upper limb decline at p=0.03 that was already on the record. An earlier update on our preview page repeated that framing and has been corrected.

Nothing about the efficacy package changed this week. What changed is which part of it Capricor is asking the FDA to approve.

The Options Angle

The reason to look at options here was a dated binary, and it has been removed. August monthly expiry is August 21, the day before the old PDUFA date, which is why the front month carried the event premium at all. Once the amendment is filed and the extension is confirmed, that expiry contains no catalyst, and premium bought for an event that has been rescheduled decays without needing the stock to move.

That argues for selling August premium rather than buying it, and it is a call I cannot price. No live chain could be sourced this session, and on a $6 stock that just traded 21 times its average volume with a 34% intraday range, the bid-ask spread on a thin contract is a large fraction of the edge. A straddle buyer here is now paying for a date that does not exist. I would rather be short that premium than long it, and I am not putting a number on it without a quote.

Trade log

#	Stance	Structure	Strikes and expiry	Cost or credit	Spot at writing	Implied move	Conviction	Breakeven
1	Pass (graded loss)	Any directional options structure into Aug 22, logged Aug 12	N/A	Pricing not sourced	$3.93 (Aug 11 close)	Not sourced	Not recorded	Stock closed $6.65, +69.2%
2	Pass	Short August premium against the vanished catalyst	Aug 21 expiry	Not sourced	$6.65 (Aug 14 close)	Not sourced	4/10	N/A

Row 2 is a pass on a view I am willing to state anyway, which is the uncomfortable version. The reasoning is sound and the instrument is untradeable at a price I can verify, so it stays a logged opinion rather than a scoreable structure. What would change it: a sourced August chain, and a confirmed replacement PDUFA date.

The One-Line Read

I read the trial correctly and the calendar naively. August 22 was never a settlement date, because Capricor could move it, and moving it was worth 58% in a stock the market had already written down to its cash.